Private OMNI canaloplasty MIGS glaucoma surgery London — UK 2026 pathway guide

What is OMNI canaloplasty and why does it differ from other MIGS?

Open-angle glaucoma is driven by raised intraocular pressure, which is itself driven by resistance to aqueous outflow at three sequential anatomical levels: the trabecular meshwork (the sieve immediately inside the iridocorneal angle), Schlemm’s canal (the circumferential channel just beyond the meshwork) and the distal collector channel system (the venous network that drains aqueous to the episcleral veins). Most MIGS devices target only one of these levels — iStent inject W and Hydrus bypass the trabecular meshwork; XEN gel stent bypasses everything to the sub-conjunctival space; trabeculectomy creates a manual bypass altogether.

The OMNI Surgical System is the only ab interno MIGS device that targets all three conventional-outflow levels in a single procedure. The cannula is introduced through a 1.6 mm temporal clear-corneal incision and, under direct gonioscopic visualisation, advanced through the trabecular meshwork into Schlemm’s canal. A microcatheter is threaded circumferentially around the canal for 360 degrees, with controlled delivery of approximately 8-12 microlitres of cohesive viscoelastic, viscodilating the canal and rupturing the collagenous herniations that occlude the collector channel ostia. The microcatheter is then withdrawn, and in the same procedure 180 degrees of the trabecular meshwork is incised by drawing the cannula across the trabecular meshwork to create a goniotomy.

The combined mechanism is biologically rational: the trabeculotomy removes the principal site of outflow resistance, the viscodilation re-opens the canal and the collector channels, and the absence of any implant or bleb avoids the maintenance and failure modes of stent or filtration surgery. The procedure preserves conjunctiva entirely — an important consideration for any patient who may need filtration surgery (trabeculectomy or Preserflo) in the future, since virgin conjunctiva is essential for those operations to succeed.

OMNI is performed as a day case under topical anaesthesia (drops only) or a sub-Tenon’s block, depending on patient cooperation and surgeon preference. The total operative time when performed alone is typically 20-30 minutes; when combined with cataract phacoemulsification, the entire combined procedure runs to 30-45 minutes including the few minutes added for the OMNI portion at the end of cataract surgery. The patient walks out of theatre, recovers briefly in the day-case unit and is discharged within an hour or two with topical antibiotic and steroid drops.

UK 2026 OMNI canaloplasty pricing, in detail

Below is a typical UK 2026 private fee structure for OMNI canaloplasty at a CQC-registered London glaucoma centre. Pricing varies by whether the procedure is standalone or combined with cataract surgery, whether topical or sub-Tenon’s anaesthesia is used, and whether you are self-pay or insurance-funded.

For comparison with other MIGS or filtration options, see private iStent inject W MIGS, private Hydrus microstent, private XEN gel stent, private Preserflo MicroShunt and private trabeculectomy. For the underlying disease, see primary open-angle glaucoma and ocular hypertension.

What a quality UK OMNI canaloplasty package should include

When you read a private quote for OMNI, check it explicitly covers each of the following. If any line is excluded you will pay it on top.

• Consultant glaucoma surgeon — GMC-registered consultant ophthalmologist with a completed glaucoma fellowship, a substantive NHS glaucoma post, and a documented case-volume of at least 50-100 OMNI procedures (the device has a defined learning curve).
• Genuine Sight Sciences OMNI device — Single-use device with full batch traceability and intact sterile packaging; the trabeculotomy mechanism and viscoelastic dispensing system are integrated.
• Pre-operative gonioscopy — Direct or indirect gonioscopy to confirm an open angle, classify the angle structures and exclude peripheral anterior synechiae that would limit canalisation.
• OCT of optic nerve and ganglion cell complex — Baseline retinal nerve fibre layer and ganglion cell complex measurements with Heidelberg Spectralis or Cirrus HD-OCT; benchmark for progression.
• Reliable visual field baseline — Two to three Humphrey 24-2 SITA-Standard or SITA-Fast fields prior to surgery to establish a defensible baseline for postoperative progression monitoring.
• Pachymetry / central corneal thickness — Influences how applanation IOP is interpreted; documented at baseline.
• CQC-registered ophthalmic day-case theatre — Inspected and rated ‘Good’ or ‘Outstanding’ on Safe and Effective domains.
• Sub-Tenon’s block option — Topical-only anaesthesia is adequate for most patients but sub-Tenon’s should be available for those who need it (particularly nervous patients or those with deep-set eyes).
• Intra-operative direct gonioscopic visualisation — A surgical gonioscopy lens (Swan-Jacob, Vold, or similar) for direct visualisation of the trabecular meshwork during cannulation.
• Standard postoperative drop regime — Topical antibiotic for 1 week and a tapering topical steroid over 4-6 weeks; written taper schedule provided.
• Reconciliation of pre-existing glaucoma drops — Many patients can stop one or more topical medications postoperatively; the consultant should review and document medication changes at each visit.
• Day 1, week 1 and week 4 reviews — Slit-lamp, applanation IOP, and gonioscopy to confirm trabeculotomy patency and absence of synechiae.
• Three-month OCT and visual field check — Progression assessment and treatment-response evaluation; usually within the surgical package.

Evidence base — what the OMNI literature shows

OMNI is one of the most-trialled MIGS platforms with consistent 24-month outcome data across standalone and combined-with-cataract settings.

• ROMEO (combined with cataract, standalone) — Prospective multicentre study evaluating OMNI combined with phacoemulsification; demonstrated significant IOP reduction and medication burden reduction at 24 months.
• GEMINI (combined with cataract) — Multicentre prospective study of OMNI plus cataract surgery; mean IOP reduction approximately 25-30% and mean medication count reduction approximately 50% sustained to 24 months.
• GEMINI 2 (standalone in pseudophakic eyes) — Pivotal evidence for standalone OMNI in patients who have already had cataract surgery; comparable IOP and medication-burden reduction to combined-procedure data.
• ROMEO 2 (multi-year follow-up) — Extended follow-up of the ROMEO cohort confirming durability of IOP and medication reduction at 3 years.
• NICE IPG700 (2021) — NICE interventional procedures guidance: ab interno canaloplasty for primary open-angle glaucoma is supported with standard clinical governance arrangements.
• UKEGS MIGS guidance — UK and Eire Glaucoma Society guidance on the place of MIGS in mild-to-moderate primary open-angle glaucoma.
• AAO Preferred Practice Pattern (Primary Open-Angle Glaucoma) — American Academy of Ophthalmology PPP places MIGS as an option in mild-to-moderate POAG, particularly where medical therapy tolerability or adherence is an issue.
• Schlemm’s canal anatomy and outflow physiology — Johnstone MA. The aqueous outflow system — Schlemm’s canal anatomy and the rationale for canaloplasty.
• Comparator MIGS evidence (iStent inject W, Hydrus) — iStent inject W (Glaukos) and Hydrus (Alcon) phase 3 trials provide the comparator IOP-reduction benchmark of approximately 20% and one-medication reduction at 24 months.
• XEN gel stent and Preserflo MicroShunt evidence — Comparator subconjunctival filtration data for moderate-to-advanced disease and failed medical therapy.
• UK CQC glaucoma service quality framework — Care Quality Commission expectations for private ophthalmic glaucoma services.

OMNI canaloplasty versus the other glaucoma surgical options

MIGS is now a crowded field. The choice between OMNI, stents, gel implants and traditional filtration depends on disease severity, anatomy, prior surgery, conjunctival status and the patient’s tolerance for medication.

• iStent inject W (Glaukos) — Two trabecular bypass stents inserted across the meshwork; technically simpler and shorter operative time than OMNI but targets only the trabecular meshwork. Reasonable choice when MIGS is being added to straightforward cataract surgery for mild glaucoma.
• Hydrus microstent (Alcon) — 8 mm nitinol scaffold dilating Schlemm’s canal across 90 degrees; HORIZON trial gives strong evidence base. Conceptually closer to OMNI than to stents but does not perform a trabeculotomy.
• KDB goniotomy (Kahook Dual Blade) — Goniotomy device that excises a strip of trabecular meshwork — cheaper than OMNI and effective for trabecular-targeted outflow improvement, but does not address the canal or collector channels.
• Gonioscopy-assisted transluminal trabeculotomy (GATT) — Microcatheter-based 360-degree trabeculotomy without viscodilation; cheaper device cost than OMNI but with a steeper learning curve and historically higher transient hyphaema rate.
• XEN gel stent (Allergan/AbbVie) — Subconjunctival filtration via a 6 mm gelatin stent; targets moderate-to-severe disease and works in eyes where conventional-outflow MIGS would be inadequate; requires healthy conjunctiva and intensive postoperative bleb management.
• Preserflo MicroShunt (Santen) — External ab externo filtration device for moderate-to-severe glaucoma; greater IOP reduction than MIGS but greater early hypotony risk and longer recovery.
• Trabeculectomy — The traditional filtration operation; greatest absolute IOP reduction but slowest recovery, highest maintenance and most cumulative complication burden — reserved for moderate-to-advanced disease, failed MIGS or filtration revision.
• Selective laser trabeculoplasty (SLT) — Office-based laser; LiGHT trial supports SLT as first-line in newly diagnosed POAG, with surgery reserved for failure of laser and medical therapy.
• Medical therapy alone (topical drops) — Most patients with mild POAG are managed on prostaglandin analogues alone for years; OMNI becomes attractive when drop adherence, drop tolerability or breakthrough progression demands surgical intervention.

Who is private OMNI canaloplasty the right choice for?

OMNI is at its best in patients with mild-to-moderate primary open-angle glaucoma where the conventional outflow pathway is the principal site of resistance and the conjunctiva should be preserved for future surgical options.

• Mild-to-moderate primary open-angle glaucoma — Mean deviation on Humphrey 24-2 better than approximately -12 dB; cup-to-disc ratio <0.85; preserved ganglion cell complex on OCT.
• Ocular hypertension with high-risk features — IOP persistently above 24-26 mmHg with thin pachymetry or strong family history, where lifelong topical therapy is unattractive.
• Pseudoexfoliation glaucoma in early stages — PXF often responds well to canaloplasty given the heavy trabecular meshwork pigmentation.
• Pigmentary glaucoma in early stages — Similar logic to PXF: trabecular meshwork is the rate-limiting site of resistance.
• Patients undergoing cataract surgery with co-existing glaucoma — Combined OMNI-phaco is one of the most efficient and cost-effective ways to address both conditions in one anaesthetic episode.
• Patients with poor topical drop adherence — Surgical reduction of medication burden is often life-changing for patients who struggle with multi-drop regimens, eye-drop technique or systemic side-effects of beta-blockers and CAIs.
• Patients with topical-drop intolerance — Allergic conjunctivitis, ocular surface disease from preservatives (benzalkonium chloride) or systemic side-effects from beta-blockers and alpha-agonists make medication-sparing surgery attractive.
• Patients with healthy conjunctiva who may need future filtration — OMNI is conjunctiva-sparing — an important consideration for younger patients who may need XEN, Preserflo or trabeculectomy in 10-20 years.
• Patients on anticoagulation — OMNI can be performed safely on warfarin, DOACs and dual antiplatelet therapy without medication interruption.
• Patients seeking faster recovery than filtration surgery — MIGS recovery is days, not weeks; visual rehabilitation matches that of routine cataract surgery.
• Patients who have failed SLT — Failure or fall-off of SLT effect at 1-3 years is a reasonable trigger to consider OMNI or another MIGS.
• Working-age patients prioritising minimal disruption — Same-day surgery, return to office work within 1 week and minimal restriction on activities makes OMNI compatible with working life.

NHS versus private OMNI canaloplasty

OMNI canaloplasty is available on the NHS at a small number of tertiary glaucoma units in England, Scotland, Wales and Northern Ireland, but it is not universally commissioned and access varies dramatically by region. NICE IPG700 (2021) supports the procedure with standard clinical governance arrangements, but it does not impose a commissioning duty — meaning whether your local NHS trust offers OMNI depends entirely on whether the glaucoma service has invested in the device and trained surgeons.

Waiting times for elective glaucoma surgery on the NHS in 2026 commonly run 6-18 months, longer in some integrated care boards. For mild-to-moderate POAG this is usually clinically acceptable — disease progression is slow on adequate medical therapy — but it can be frustrating for patients keen to escape drop burden, and it can be clinically problematic for patients showing breakthrough progression on maximal medical therapy. The private pathway typically offers consultation within a week, surgical date within 2-4 weeks of decision, and the same consultant performing both the assessment and the surgery.

Many patients with glaucoma already use a hybrid pathway: NHS for routine monitoring (visual fields, OCT) and private for surgical intervention. This works well provided the NHS service accepts the postoperative referral and continues progression monitoring without re-listing for unnecessary investigations. The receiving NHS consultant typically welcomes the surgical letter, the device record and the postoperative gonioscopy findings.

Private medical insurance and OMNI canaloplasty

Bupa, AXA Health, Aviva, Vitality and WPA all cover OMNI canaloplasty under their standard glaucoma surgical pathways subject to your specific policy benefits, excess and pre-authorisation requirements. Glaucoma is generally treated as a chronic condition and most policies will pay for the surgical episode (consultation, surgery, device, theatre and postoperative care to 3 months) but may not cover ongoing chronic-condition reviews thereafter. CCSD procedure codes for ab interno canaloplasty and combined cataract surgery are established, and the OMNI device is typically billed as an itemised consumable on top of the procedure code. Pre-authorisation requires the consultant’s assessment letter, visual fields, OCT and the planned procedure code; the clinic’s administrative team typically handles the submission. Where MIGS is combined with cataract surgery, insurers normally pay for both procedures in the same anaesthetic episode without double-counting the theatre fee. Premium IOL upgrades (toric or EDOF lenses) are usually self-funded on top of the insured cataract portion.

Risks of OMNI canaloplasty

OMNI is one of the safer glaucoma surgical procedures, but it is intraocular surgery and the risks below are individually rare but not zero.

• Transient hyphaema (blood in the anterior chamber) — Common (15-30% of eyes) in the first few days after the trabeculotomy portion, due to reflux of blood from Schlemm’s canal; usually clears spontaneously in 3-7 days and rarely requires intervention.
• Transient IOP spike — An IOP spike in the first 1-2 weeks postoperatively occurs in approximately 5-10% of eyes, due to viscoelastic retention or inflammatory blockage; managed with extra topical drops or rarely an anterior chamber washout.
• Postoperative IOP not falling to target — Approximately 10-20% of eyes do not achieve the desired IOP at 6 months and require either continued topical therapy or escalation to subconjunctival filtration.
• Endophthalmitis — <1 in 1,000 risk for any intraocular procedure; presents at days 3-7 with pain, vision loss and hypopyon; managed with same-day vitreoretinal tap-and-inject.
• Cyclodialysis cleft (rare) — An inadvertent separation of the ciliary body from the scleral spur can cause profound hypotony; vanishingly rare with OMNI in trained hands.
• Descemet’s membrane detachment — Localised detachment from cannula entry; usually resolves spontaneously with intracameral air if needed.
• Cataract progression (in phakic eyes) — Any intraocular surgery accelerates nuclear sclerosis modestly; this is usually pre-empted by performing OMNI combined with cataract surgery in patients with co-existent nuclear sclerosis.
• Iridocyclitis — Mild postoperative inflammation is expected and managed with the standard 4-6 week tapering topical steroid; persistent inflammation is uncommon.
• Peripheral anterior synechiae formation — Adhesions between the iris and the gonioscopic angle can form at the trabeculotomy site; usually small and clinically silent but should be documented at the postoperative gonioscopy review.
• Vision loss (severe) — Severe permanent vision loss from intraocular surgery is <1 in 1,000 across all causes; the most-feared cause is endophthalmitis.
• Loss of subsequent filtration option — OMNI is conjunctiva-sparing and does not compromise future trabeculectomy or XEN; this is a key safety feature relative to procedures that violate the conjunctiva.
• Need for re-operation — Approximately 5-15% of eyes need additional glaucoma intervention within 2-3 years, depending on baseline disease severity and IOP target.
• Anaesthesia-related risks — Topical or sub-Tenon’s anaesthesia avoids general anaesthetic risk almost entirely; rare retrobulbar haemorrhage with peri-bulbar block.
• Failure to relieve medication burden — Even in successful cases, approximately 30-40% of patients still require one topical glaucoma medication at 24 months; the realistic expectation is medication reduction rather than complete medication freedom.

Recovery after OMNI canaloplasty

OMNI canaloplasty is a day-case procedure. You arrive at the day-case unit a couple of hours before surgery, undergo final assessment and consent, are taken to theatre for the 20-30 minute procedure (or 30-45 minutes combined with cataract surgery), recover briefly in the day-case unit and are discharged the same day. The eye is patched for the first few hours and reviewed at day 1.

In the first week, vision is typically misty rather than sharp — the cornea has been touched by the cannula, the viscoelastic takes 24-48 hours to clear, and a small hyphaema (blood in the anterior chamber) is common and often visible as a settled fluid level. Most patients see well enough to read large print and watch television from day 2-3 and notice steady improvement over the first 2 weeks. Combined OMNI-phaco patients follow the standard cataract surgery visual recovery trajectory, typically reaching their best vision at 3-6 weeks once the IOL is stable.

The topical drop regime is a tapering topical steroid (typically dexamethasone or prednisolone four times daily, tapered to none over 4-6 weeks) plus an antibiotic for the first 7 days. Many patients can stop one or more of their pre-operative glaucoma drops immediately after surgery on the consultant’s instruction; some are held on their existing regime for the first month and tapered at the week-4 review based on IOP.

Activity restrictions are minimal: no rubbing the eye, no swimming or hot tubs for 2 weeks, no contact sports for 4 weeks. Reading, screen work, light gym exercise and driving (once vision is adequate, typically day 2-7) are unrestricted. Most office-based workers return to work within 3-7 days and manual workers within 2-3 weeks.

Red-flag symptoms to escalate to the 24/7 clinic line immediately: severe pain not relieved by simple analgesia, rapidly worsening vision over hours, marked redness with pus-like discharge, a visible white fluid level in the front of the eye (hypopyon), new flashes or floaters or a curtain visual field defect. Endophthalmitis is rare but time-critical and presents at days 3-7. The next milestones are the day 1 review, week 1 review, week 4 review, and 3-month progression check with OCT and visual fields.

How to choose a London clinic for OMNI canaloplasty

MIGS is the most technique-dependent area of glaucoma surgery. Outcomes vary significantly with surgeon experience, gonioscopic skill and case selection.

• Consultant with a completed glaucoma fellowship — GMC-registered consultant ophthalmologist with a 12-month minimum subspecialty glaucoma fellowship and a substantive NHS glaucoma post.
• Documented OMNI case volume — Ask how many OMNI procedures the surgeon has performed; 50-100 is a reasonable threshold for the principal learning curve. The Sight Sciences certification programme records this.
• UKEGS membership — United Kingdom and Eire Glaucoma Society membership signals subspecialty engagement and ongoing CPD.
• CQC inspection rating — Care Quality Commission report on the day-case unit; you want ‘Good’ or ‘Outstanding’ on Safe and Effective domains.
• Pre-operative gonioscopy as part of consultation — If the surgeon hasn’t performed gonioscopy on you before quoting MIGS, the assessment is incomplete — the angle anatomy determines candidacy.
• Heidelberg Spectralis or Cirrus HD-OCT — Gold-standard imaging for optic nerve and ganglion cell complex; older Stratus units are usable but less reliable for progression.
• Humphrey or equivalent visual field platform — Reliable 24-2 SITA-Standard or SITA-Fast testing; ideally with progression-analysis software for longitudinal assessment.
• Combined OMNI-phaco capability if needed — Most glaucoma surgeons also operate on cataract; combined operating list capacity is important to avoid two separate theatre episodes.
• Transparent quoting including device cost — OMNI is an itemised single-use device costing the clinic several hundred pounds; the quote should specify the device by name.
• Written postoperative drop tapering plan — Provided at discharge; covers steroid taper, antibiotic course and reconciliation of pre-existing glaucoma medications.
• 24/7 contact for postoperative complications — Written telephone pathway to a glaucoma or general ophthalmology on-call surgeon within hours of new symptoms.

Frequently asked questions

Methodology and sources

This page is built from peer-reviewed RCT and prospective cohort data, UK regulatory and society guidance, and the practical experience of UK CQC-registered private glaucoma services. Prices reflect typical UK 2026 self-pay rates at London glaucoma centres at the time of publication.

• ROMEO multicentre prospective study of OMNI canaloplasty.
• ROMEO 2 extended-follow-up cohort.
• GEMINI multicentre study of OMNI combined with cataract surgery (24-month outcomes).
• GEMINI 2 standalone OMNI in pseudophakic eyes.
• NICE Interventional Procedures Guidance 700 (IPG700): Ab interno canaloplasty for primary open-angle glaucoma.
• UK and Eire Glaucoma Society (UKEGS) guidance on MIGS.
• American Academy of Ophthalmology Preferred Practice Pattern: Primary Open-Angle Glaucoma.
• European Glaucoma Society Terminology and Guidelines for Glaucoma (5th edition).
• LiGHT trial (Selective laser trabeculoplasty as first-line treatment of POAG) for comparator reference.
• HORIZON trial (Hydrus microstent) and iStent inject W phase 3 trials for comparator MIGS evidence.
• Royal College of Ophthalmologists glaucoma clinical guideline.
• Sight Sciences OMNI technical reference and surgeon training materials.
• Care Quality Commission inspection framework for ophthalmic day-case providers.

This page is editorial and educational. It is not personalised medical advice. Suitability for OMNI canaloplasty, the choice of anaesthetic, the decision to combine with cataract surgery and the postoperative drop regime are individual decisions made between you and a GMC-registered consultant glaucoma surgeon following a full clinical assessment including gonioscopy. Prices are typical UK 2026 ranges at CQC-registered London centres and may vary.

Book your London OMNI canaloplasty consultation

If you are on multiple glaucoma drops, struggling with adherence or tolerability, or showing breakthrough progression on medical therapy, OMNI canaloplasty may offer a meaningful reduction in medication burden and a path to better IOP control with a fast recovery. Our consultants are GMC-registered glaucoma surgeons with completed glaucoma fellowships, UKEGS membership and substantive NHS glaucoma posts. Call us or use the appointment form to arrange a consultation including gonioscopy, OCT and visual field testing.

Related reading: Private iStent inject W MIGS · Private Hydrus microstent · Private XEN gel stent · Private Preserflo MicroShunt · Primary open-angle glaucoma